Sunshine Biopharma (SBFM) Cost of Revenue (2018 - 2026)

Sunshine Biopharma's Cost of Revenue history runs 9 years deep, the most recent figure standing at $250223.0 for Q1 2026.

• Quarterly Cost of Revenue fell 37.19% year-over-year to $250223.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.0 million (up 175.96% YoY) and the FY2025 annual result came in at $24.1 million, up 2457.78% from the prior year.
• Cost of Revenue was $250223.0 for Q1 2026 at Sunshine Biopharma, down from $5.5 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $6.0 million in Q2 2025 and bottomed at -$16.8 million in Q4 2024.
• A 5-year average of $180320.5 and a median of $241897.0 in 2023 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2023 — Cost of Revenue surged 4015.1% — and 2024, when it plunged 7348.2%.
• Sunshine Biopharma's Cost of Revenue stood at $2.2 million in 2022, then sank by 89.72% to $231261.0 in 2023, then plunged by 7348.2% to -$16.8 million in 2024, then soared by 133.1% to $5.5 million in 2025, then plunged by 95.49% to $250223.0 in 2026.
• Business Quant data shows SBFM's Cost of Revenue at $250223.0 in Q1 2026, $5.5 million in Q4 2025, and $235217.0 in Q3 2025.